In our group, we have developed a quantitative PCR technique in the presence of PNA to detect EGFR, KRAS, and BRAF mutations in the cfDNA of advanced lung, colon, and cancer patients that achieves 75–80% sensitivity with 100% specificity (18, 19). This evidence concerns the gene EGFR and cancer.